Phase II Multicenter Study of Enzalutamide in Metastatic Castration-Resistant Prostate Cancer to Identify Mechanisms Driving Resistance
Rana R McKay,Lucia Kwak,Jett P Crowdis,Jamie M Sperger,Shuang G Zhao,Wanling Xie,Lillian Werner,Rosina T Lis,Zhenwei Zhang,Xiao X Wei,Joshua M Lang,Eliezer M Van Allen,Rupal S Bhatt,Evan Y Yu,Peter S Nelson,Glenn J Bubley,R Bruce Montgomery,Mary-Ellen Taplin,Rana R. McKay,Jett P. Crowdis,Jamie M. Sperger,Shuang G. Zhao,Rosina T. Lis,Xiao X. Wei,Joshua M. Lang,Eliezer M. Van Allen,Rupal S. Bhatt,Evan Y. Yu,Peter S. Nelson,Glenn J. Bubley,R. Bruce Montgomery
DOI: https://doi.org/10.1158/1078-0432.ccr-20-4616
IF: 13.801
2021-04-13
Clinical Cancer Research
Abstract:Abstract Purpose: Enzalutamide is a second-generation androgen receptor (AR) inhibitor that has improved overall survival (OS) in metastatic castration-resistant prostate cancer (CRPC). However, nearly all patients develop resistance. We designed a phase II multicenter study of enzalutamide in metastatic CRPC incorporating tissue and blood biomarkers to dissect mechanisms driving resistance. Patients and Methods: Eligible patients with metastatic CRPC underwent a baseline metastasis biopsy and then initiated enzalutamide 160 mg daily. A repeat metastasis biopsy was obtained at radiographic progression from the same site when possible. Blood for circulating tumor cell (CTC) analysis was collected at baseline and progression. The primary objective was to analyze mechanisms of resistance in serial biopsies. Whole-exome sequencing was performed on tissue biopsies. CTC samples underwent RNA sequencing. Results: A total of 65 patients initiated treatment, of whom 22 (33.8%) had received prior abiraterone. Baseline biopsies were enriched for alterations in AR (mutations, amplifications) and tumor suppression genes (PTEN, RB1, and TP53), which were observed in 73.1% and 92.3% of baseline biopsies, respectively. Progression biopsies revealed increased AR amplifications (64.7% at progression vs. 53.9% at baseline) and BRCA2 alterations (64.7% at progression vs. 38.5% at baseline). Genomic analysis of baseline and progression CTC samples demonstrated increased AR splice variants, AR-regulated genes, and neuroendocrine markers at progression. Conclusions: Our results demonstrate that a large proportion of enzalutamide-treated patients have baseline and progression alterations in the AR pathway and tumor suppressor genes. We demonstrate an increased number of BRCA2 alterations post-enzalutamide, highlighting the importance of serial tumor sampling in CRPC.
oncology